Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 117.20B |
| Revenue (ttm) | 55.55B |
| Net Income (ttm) | 2.36B |
| Shares Out | n/a |
| EPS (ttm) | 2.04 |
| PE Ratio | 49.64 |
| Forward PE | 12.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,420,105 |
| Average Volume | 1,354,290 |
| Open | 10,120 |
| Previous Close | 10,130 |
| Day's Range | 10,060 - 10,310 |
| 52-Week Range | 4,865 - 11,100 |
| Beta | 0.66 |
| RSI | 62.08 |
| Earnings Date | Jan 28, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
Teva (TEVA) Gains FDA Approval for Ajovy in Pediatric Migraine Treatment
Teva (TEVA) Gains FDA Approval for Ajovy in Pediatric Migraine Treatment
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the N...
Teva Is No Longer A Turnaround Story, It's A Growth One
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial
A Georgia federal judge on Monday reportedly denied Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) a request to delay the first trial in thousands of lawsuits alleging its Paragard intrauterine dev...
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva Pharmaceutical Industries Ltd . (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva’s...
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's an...
Why Investors Are So Optimistic on Teva
Teva Pharmaceuticals stock jumped Monday after the drugmaker issued upbeat guidance and targets for the years ahead.
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Teva Pharmaceutical (TEVA) Projects Higher EPS and Revenue Outlook
Teva Pharmaceutical (TEVA) Projects Higher EPS and Revenue Outlook
Teva Pharmaceutical sees 2025 EPS at higher range of outlook
Teva (TEVA) Secures $500M Funding for Vitiligo Therapy Development
Teva (TEVA) Secures $500M Funding for Vitiligo Therapy Development
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment
Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment
(RTTNews) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have announced a funding agreement of up to $500 million to advance the...
Teva Pharmaceutical (TEVA) Projects Revenue Between $16.8B and $17B for FY25
Teva Pharmaceutical (TEVA) Projects Revenue Between $16.8B and $17B for FY25
Teva (TEVA) Projects Significant Growth in FY30 with Strong Cash Flow
Teva (TEVA) Projects Significant Growth in FY30 with Strong Cash Flow
Teva Pharmaceutical (TEVA) Projects Strong FY30 Financial Performance
Teva Pharmaceutical (TEVA) Projects Strong FY30 Financial Performance
TEVA Expects FY27 EBITDA Growth and Net Cash Flow Increase
TEVA Expects FY27 EBITDA Growth and Net Cash Flow Increase
TEVA Forecasts Growth in FY26 Adjusted EBITDA and Free Cash Flow
TEVA Forecasts Growth in FY26 Adjusted EBITDA and Free Cash Flow
Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development
(RTTNews) - Royalty Pharma plc (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have entered into a funding agreement of up to $500 million to accelerat...
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard F...
Royalty Pharma (RPRX) Partners with Teva for $500M Drug Development Funding
Royalty Pharma (RPRX) Partners with Teva for $500M Drug Development Funding